Sezgin Orhan, Barlas I Omer, Uçbilek Enver, Yengel Emre, Altintaş Engin
Acta Gastroenterol Belg. 2014 Mar;77(1):3-7.
To investigate whether the sequential therapy composed of high dose omeprazole and high dose amoxicillin in the first step was effective in eradication of H. pylori and whether there was a relation between effectiveness of the therapy and CYP2C19 gene polymorphism.
134 dyspeptic patients with H. pylori were administered a modified sequential therapy composed of omeprazole 40 mg t.i.d. and amoxicillin 1000 mg t.i.d, for the first five days followed by omeprazole 20 mg b.d., metronidazole 500 mg t.i.d. and tetracycline 500 mg t.i.d, for the next five days. CYP2C19 genotype status was determined in patients. Hp eradication status was investigated by C14 UNT four weeks after treatment.
The eradication rates were 64.9% in ITT and 74.3% in PP analysis. In subgroup analyses, eradication rates were 73.8% and 60.8% (p: 0.145) in ITT for peptic ulcer and non-ulcer dyspepsia patients respectively and 86.1% and 69.1% (p: 0.052) in PP analysis for peptic ulcer and non-ulcer dyspepsia patients respectively. The difference was not significant. As for the CYP2C19 gene status, 81.5% of the patients had HoEM and 17.3% of the patients had HeEM, and eradication rates were 72% and 75% in ITT analysis for HoEM and HeEM respectively (p: 0.803) and 73.9% and 85.7% in PP analysis for HoEM and HeEM respectively (p: 0.347). There was not a significant difference in H. pylori eradication rates between the two groups.
This modified high-dose sequential therapy was ineffective in a Turkish sample, nearly all of whom had EM in terms of CYP2C19 gene status.
探讨第一步采用大剂量奥美拉唑和大剂量阿莫西林的序贯疗法根除幽门螺杆菌是否有效,以及该疗法的有效性与CYP2C19基因多态性之间是否存在关联。
对134例幽门螺杆菌感染的消化不良患者采用改良序贯疗法,前五天给予奥美拉唑40毫克每日三次和阿莫西林1000毫克每日三次,接下来五天给予奥美拉唑20毫克每日两次、甲硝唑500毫克每日三次和四环素500毫克每日三次。测定患者的CYP2C19基因型状态。治疗四周后通过C14尿素呼气试验调查幽门螺杆菌根除情况。
意向性分析(ITT)中的根除率为64.9%,符合方案分析(PP)中的根除率为74.3%。在亚组分析中,消化性溃疡患者和非溃疡性消化不良患者在ITT中的根除率分别为73.8%和60.8%(p:0.145),在PP分析中分别为86.1%和69.1%(p:0.052)。差异无统计学意义。至于CYP2C19基因状态,81.5%的患者为纯合野生型(HoEM),17.3%的患者为杂合野生型(HeEM),在ITT分析中,HoEM和HeEM的根除率分别为72%和75%(p:0.803),在PP分析中分别为73.9%和85.7%(p:0.347)。两组之间幽门螺杆菌根除率无显著差异。
在一个土耳其样本中,这种改良的大剂量序贯疗法无效,该样本中几乎所有患者在CYP2C19基因状态方面均为野生型。